#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The timing for CV risk intervention as a critical success factor


Authors: Zuzana Zafarová;  Michal Vrablík
Authors‘ workplace: Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in: AtheroRev 2020; 5(2): 127-130
Category:


Sources
  1. Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.
  2. Baigent C, Blackwell L, Emberson J et al.[ Cholesterol Treatment Trialists’ (CTT) Collaboration]. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.
  3. Vrablík M, Chmelík Z, Lánská V. Kardiovaskulární rizikový profil 40letých mužů a 50letých žen v ordinacích praktických lékařů. Practicus 2015; 14(8): 15–19.
  4. Thoenes M, Bramlage P, Zhong S et al. Hypertension Control and Cardiometabolic Risk: A Regional Perspective. Cardiol Res Pract 2012; 2012: 925046. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/925046>.
  5. Tůmová E, Šatný M, Vrablík M. Doporučení v praxi: jak a proč (ne)dosahují pacienti s hypertenzí a dyslipidemií cílových hodnot Výsledky průzkumu LIPIcontrol. Medicína po promoci 2018; 19(3): 269–273.
  6. Robinson JG, Williams KJ, Gidding S et al. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc 2018; 7(20): e009778. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.118.009778>.
  7. Ference BA, Majeed F, Penumetcha R et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015; 65(15): 1552–1561. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.02.020>.
  8. Ference BA, Julius S, Mahajan N et al. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension 2014; 63(6): 1182–1188. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.02734>.
  9. Ford I, Murray H, McCowan C et al. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation 2016; 133(11): 1073–80. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019014>.
  10. Gupta A, Mackay J, Whitehouse A et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet 2018; 392(10153): 1127–1137. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)31776–8>. Erratum in Department of Error. [Lancet 2018].
  11. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25(6): 484–491. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ehj.2003.11.012>.
  12. Coleman CI, Roberts MS, Sobieraj DM et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28(5): 669–680. Dostupné z DOI: <http://dx.doi.org/10.1185/03007995.2012.677419>.
  13. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9(9 Suppl): 2–6.
  14. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147–1152. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.10.1147>.
  15. Böhm M, Schumacher H, Laufs U et al. Effects of nonpersistance with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013; 166(2): 306–314.e7. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2013.04.016>.
  16. Shin S, Jang S, Lee TJ et al. Association between non-adherence to statin and hospitalization for cardiovascular disease and all-cause mortality in a national cohort. Int J Clin Pharmacol Ther 2014; 52(11): 948–956. <http://dx.doi.org/10.5414/CP202132>.
  17. Yusuf S, Pais P, Afzal R et al. Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373(9672): 1341–1351. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60611–5>.
  18. Malekzadeh F, Marshall T, Pourshams A et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (’polypill’) on cardiovascular risk factors. Int J Clin Pract 2010; 64(9): 1220–1227. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1742–1241.2010.02412.x>.
  19. Rodgers A, Patel A, Berwanger O et al. [Collaborative Group PILL]. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One 2011; 6(5): e19857. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0019857>. Erratum in Correction: An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. [PLoS One. 2019].
  20. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One 2012; 7: e41297. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0041297>.
  21. Thom S, Poulter N, Field J et al. [UMPIRE Collaborative Group]. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310(9): 918–929. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2013.277064>. Erratum in JAMA 2013; 310(14): 1507.
  22. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005 May 23; 165(10): 1147–1152. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.10.1147>.
  23. Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm 2005; 62(23): 2491–2494. Dostupné z DOI: <http://dx.doi.org/10.2146/ajhp050072>.
  24. Euvascor. Souhrn údajů o přípravku. Dostupné z WWW: <http://www.sukl.cz>.
  25. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149–1158. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(03)12948–0>.
  26. van der Leeuw J, Oemrawsingh RM, van der Graaf Y et al. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease – results from EUROPA. Int J Cardiol. 2015; 182: 194–199. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2014.12.046>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Article was published in

Athero Review

Issue 2

2020 Issue 2

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#